Clinical Trial Update: Afatinib in Lung Cancer With EGFR Mutation From Circulating Tumor DNA [Phase 2]

View source ↗

Summary

A phase 2 clinical trial evaluating afatinib in lung cancer patients with EGFR mutations using circulating tumor DNA as a biomarker.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Neoplasms

Drugs mentioned

• Afatinib (afatinib)

Snippet

Sponsor: Chonnam National University Hospital | Conditions: Lung Neoplasms, EGFR Gene Mutation | Phase 2 | Status: COMPLETED